SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This ...
Noridian Healthcare Solutions opened a draft local coverage determination for gene tests for heritable thoracic aortic disease per a request from Invitae Corp., of San Francisco, which makes a ...
– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Invitae (NVTA ...
A retrospective study was performed to analyze the results of clinical germline genetic testing (March 2020-January 2023) among a cohort of consecutive Emirati patients at risk for hereditary breast ...
Millions of people globally struggle with rare diseases, often facing limited treatment options due to fragmented care and a lack of research resources. In many cases, the diagnostic odyssey - moving ...
A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae cut about 1,000 jobs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results